Overview
Acute myeloid leukemia with t(6;9)(p23;q34), sometimes called AML with DEK-NUP214 fusion, is a rare and aggressive type of blood cancer. In this disease, a specific genetic change occurs in the leukemia cells where parts of chromosome 6 and chromosome 9 swap places (called a translocation). This swap creates an abnormal fusion gene called DEK-NUP214, which drives the uncontrolled growth of immature white blood cells (called blasts) in the bone marrow. As these abnormal cells build up, they crowd out healthy blood cells, leading to problems like anemia, infections, and easy bleeding. Patients often experience fatigue, frequent infections, bruising, and bone pain. A notable feature of this subtype is that it is frequently associated with a condition called basophilia, meaning there are higher-than-normal levels of basophils (a type of white blood cell) in the blood. This subtype tends to affect younger adults and is considered to have a poor prognosis compared to many other forms of AML. Treatment typically involves intensive chemotherapy, and because outcomes with chemotherapy alone are often unfavorable, doctors usually recommend an allogeneic stem cell transplant (a transplant using donor cells) when possible. Newer targeted therapies and clinical trials are being explored to improve outcomes for patients with this challenging subtype. Early and accurate diagnosis through genetic testing of the leukemia cells is essential for guiding the best treatment plan.
Also known as:
Key symptoms:
Extreme tiredness and fatigueFrequent or severe infectionsEasy bruising or unusual bleedingPale skin due to anemiaBone or joint painUnexplained feversNight sweatsUnintended weight lossShortness of breathTiny red spots on the skin (petechiae)Swollen gumsFeeling full or discomfort from an enlarged spleenElevated basophil count in blood tests
Sporadic
Usually appears on its own, not inherited from a parent
Adult
Begins in adulthood (age 18 or older)
Treatments
No FDA-approved treatments are currently listed for Acute myeloid leukemia with t(6;9)(p23;q34).
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Acute myeloid leukemia with t(6;9)(p23;q34) at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Acute myeloid leukemia with t(6;9)(p23;q34).
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Acute myeloid leukemia with t(6;9)(p23;q34).
Community
No community posts yet. Be the first to share your experience with Acute myeloid leukemia with t(6;9)(p23;q34).
Start the conversation →Latest news about Acute myeloid leukemia with t(6;9)(p23;q34)
No recent news articles for Acute myeloid leukemia with t(6;9)(p23;q34).
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What does the t(6;9) translocation mean for my specific treatment plan and prognosis?,Does my leukemia also have a FLT3 mutation, and if so, should I receive a FLT3 inhibitor?,Am I a candidate for a stem cell transplant, and when should it be done?,Are there any clinical trials available for my specific subtype of AML?,What are the short-term and long-term side effects of the recommended treatment?,How will treatment affect my fertility, and should I consider fertility preservation before starting?,What support services are available to help me and my family cope during treatment?
Common questions about Acute myeloid leukemia with t(6;9)(p23;q34)
What is Acute myeloid leukemia with t(6;9)(p23;q34)?
Acute myeloid leukemia with t(6;9)(p23;q34), sometimes called AML with DEK-NUP214 fusion, is a rare and aggressive type of blood cancer. In this disease, a specific genetic change occurs in the leukemia cells where parts of chromosome 6 and chromosome 9 swap places (called a translocation). This swap creates an abnormal fusion gene called DEK-NUP214, which drives the uncontrolled growth of immature white blood cells (called blasts) in the bone marrow. As these abnormal cells build up, they crowd out healthy blood cells, leading to problems like anemia, infections, and easy bleeding. Patients
How is Acute myeloid leukemia with t(6;9)(p23;q34) inherited?
Acute myeloid leukemia with t(6;9)(p23;q34) follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Acute myeloid leukemia with t(6;9)(p23;q34) typically begin?
Typical onset of Acute myeloid leukemia with t(6;9)(p23;q34) is adult. Age of onset can vary across affected individuals.